Navigation Links
China Biologic Receives SFDA Approval for Clinical Trial of Human Coagulation Factor VIII
Date:9/17/2008

ospitals and other health care facilities in China. The Company's human albumin products are mainly used to increase blood volume and its immunoglobulin products are used for the treatment and prevention of diseases.

Safe Harbor Statement

This release may contain certain "forward-looking statements" relating to the business of China Biologic Products, Inc. and its subsidiary companies. All statements, other than statements of historical fact included herein are "forward-looking statements," including statements regarding: the significance of SFDA approval for FVIII clinical trials; the ability of the Company to continue production of Cryoprecipitate from clinical extra plasma and its effect on future profit margins; the ability of the Company to achieve its commercial objectives; the business strategy, plans and objectives of the Company and its subsidiaries; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward- looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by th
'/>"/>

SOURCE China Biologic Products, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
5. China Technology Announces New Chief Financial Officer
6. China Medical Technologies Reports First Quarter Financial Results
7. China Medical Technologies to Participate in Credit Suisses 2007 Asian Technology Conference
8. China Technology Announces Entry to the Solar Energy Sector
9. China Sky One Medical Receives $1.5 Million Government Grant to Further Develop Six New Cancer Products
10. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
11. China Kangtai Cactus Biotech, Inc. Announces Plans for New Product Launch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... , ... R-Biopharm is proud to announce the RIDASCREEN® Gliadin ... has been accepted by AOAC International as Official First Action method. The AOAC ... by R5 Competitive ELISA,” based on a specific monoclonal antibody to potentially celiac ...
(Date:7/30/2015)... AACC welcomed thousands of medical professionals ... Meeting & Clinical Lab Expo in ... showcased revolutionary advancements in clinical testing technology and ... to diagnose patients quickly and accurately and make ... As of Wednesday, July 29, more than ...
(Date:7/30/2015)... ... July 30, 2015 , ... Tronics, ... as Sales & Marketing Director. , With more than 25 years of ... for reinforcing Tronics’ business development activities worldwide. He brings to the company his ...
(Date:7/30/2015)... VANCOUVER, Washington , July 30, 2015 ... "Biosimulation Market, by Product (Software, Molecular Modeling, PB/PK, PKPD, ... (Drug Discovery & Development, Preclinical, Clinical Trial), by End ... the Biosimulation Market is expected to reach USD 2,107.99 ... at a CAGR of 15.29%. Browse ...
Breaking Biology Technology:RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Tronics appoints Francois Vieillard as Sales and Marketing Director 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4
... , , Akira Ichikawa and Seiji Igarashi , ... , Introduction ... the most consistently , used mutation scanning methods. It ... be widely used particularly in gene diagnostic laboratories. , ...
... Axel Reinecke-Lthge*, Barbara Mllmann*, Angela , Kellner, ... of Pathology and Department of Hematopathology, Christian- , ... , ... the cause underlying many non-neoplastic , and ...
... Glenn A. Miller, Ph.D., Molecular Profiling Laboratory, Genzyme, ... Introduction , ... study of genes that play a role in the development ... single and multiple gene disorders. A wide variety of different , ...
Cached Biology Technology:Detection of p53 Gene in Breast Cancer by Denaturing Gradient Gel Electrophoresis and the DCode System 2Detection of p53 Gene in Breast Cancer by Denaturing Gradient Gel Electrophoresis and the DCode System 3Detection of K-ras Point Mutations in the Pancreas by Constant Denaturing Gel Electrophoresis Using the DCode System 2Detection of K-ras Point Mutations in the Pancreas by Constant Denaturing Gel Electrophoresis Using the DCode System 3Detection of K-ras Point Mutations in the Pancreas by Constant Denaturing Gel Electrophoresis Using the DCode System 4A Multiple Mutation Model System as a Test Development and Training Tool for Denaturing Gradient Gel Electrophoresis 2A Multiple Mutation Model System as a Test Development and Training Tool for Denaturing Gradient Gel Electrophoresis 3A Multiple Mutation Model System as a Test Development and Training Tool for Denaturing Gradient Gel Electrophoresis 4A Multiple Mutation Model System as a Test Development and Training Tool for Denaturing Gradient Gel Electrophoresis 5A Multiple Mutation Model System as a Test Development and Training Tool for Denaturing Gradient Gel Electrophoresis 6A Multiple Mutation Model System as a Test Development and Training Tool for Denaturing Gradient Gel Electrophoresis 7A Multiple Mutation Model System as a Test Development and Training Tool for Denaturing Gradient Gel Electrophoresis 8
(Date:7/31/2015)... , July 31, 2015 The 10 th ... be held by BGI from October 22-25, 2015, in ... The conference is celebrating its 10 th anniversary this ... of the world,s most influential annual meetings in the ,omics, ... enjoyable scientific gatherings. ICG-10 focuses on recent ...
(Date:7/27/2015)... 27, 2015   Zynx Health ™, the ... improvement solutions, today announced that its ZynxCarebook ... on Android smartphones and tablets. With this expansion, ... can use ZynxCarebook to securely exchange messages and ... care transitions to other care settings, and improve ...
(Date:7/21/2015)... , July 21, 2015 Today, ZTE announced ... received as well as expected revenues in 2015 that relate to ... communicated revenue guidance of approximately 2,200 MSEK for 2015. ... a leading smartphone manufacturer in China and ... 02 5 for Axon , ...
Breaking Biology News(10 mins):The 10th International Conference on Genomics (ICG-10) to Open in October 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2
... On April 15, 2010 , Dr. Stipkala joined a panel ... hosted by the University of South Carolina ,s NanoCenter in ... capitalists from all over the Southeast who are active in the nanotechnology ... Dr. Stipkala and ...
... Bethesda, MD The Genetics Society of America is ... selected for poster awards at the 51st Annual Drosophila ... were selected for first, second and third place awards ... undergraduate. This was the first time that undergraduate student ...
... YORK (April 25, 2010) -- Researchers at the ... Psychiatry at Weill Cornell Medical College discovered that ... behaviors. The genetically altered mice, which behaved much ... disorder (OCD), could help scientists design new therapies ...
Cached Biology News:Dr. Jeremy M. Stipkala, Patent Attorney, Speaks on USC NanoCenter Panel 2Genetics Society of America announces award recipients at 51st Annual Drosophila Conference 2Weill Cornell researchers find that a single gene is responsible for OCD-like behaviors in mice 2Weill Cornell researchers find that a single gene is responsible for OCD-like behaviors in mice 3Weill Cornell researchers find that a single gene is responsible for OCD-like behaviors in mice 4
... / Mount is the standard water based ... especially for the permanent preservation of peroxidase ... is easy to use and exhibits excellent ... first aqueous mounting medium that permits the ...
... Immunogen: Synthetic peptide derived from an ... protein. Specificity: Specific for the ... WNT2B/WNT13 proteins. Recognizes both human WNT13A ... Human Rat (positive controls: mouse WNT2B/WNT13-pCMV-tag2-transfected ...
Immunogen: Heat inactivated bacterial cells of Salmonella enteriditis,paratyphi and typhimurium Storage: 4 C...
Immunogen: Secretory component isolated from human colostrum. Storage: 4 C...
Biology Products: